Security
Personalized vaccine reduces the risk of skin cancer recurrence or death by 42%
/file/attachments/2409/cancer-immunotherapy-e8a50f02_764883.png)
WHAT TO KNOW
Ad-Diyar: Results of an advanced clinical trial showed that an experimental personalized vaccine based on messenger RNA (mRNA) technology, developed by Merck and Moderna, helped reduce the risk of skin cancer recurrence or death by 42% when used with the immunotherapy Keytruda. The vaccine is known as…
Machine translation of an attributed source excerpt. Consult the original report to verify details. Translated from original reporting in another language.
